Skip to main content

Plasma S100P and hyaluronic acid level as prognostic and treatment monitoring markers for metastatic breast cancer

Ref-Nr: TA-P-1157


Kurzfassung

The present invention comprises the use of two serum/plasma markers for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers outperform established ones like the number of circulating tumor cells (CTCs).

Marker approved and verified in studies of 320 (S100P in combination with HA) and 334 (HA only) patients with different disease stages.

 

 


Hintergrund

The technology describe two serum/plasma markers, in combination or alone, for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers perform better than established ones like the number of circulating tumor cells (CTCs).


Bilder & Videos


Lösung

  • Discrimination between metastatic and non-metastatic breast cancer AUC of ROC curve = 0.85 .
  • Marker for diagnostic, prognostic and treatment monitoring of metastatic breast cancer .

Vorteile

  • More accurate prediction of progression-free and overall survival than presence of CTCs.
  • More accurate prediction of treatment response than presence of CTCs.

Anwendungsbereiche

Common ELISA technology has been used for detection of hyaluronic acid and S100P in plasma of breast cancer patients. 


Deutsches Krebsforschungszentrum DKFZ

Dr. Frieder Kern
+49-6221-42-2952
f.kern@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Präklinik


Stichworte

Diagnostics, Research Tools

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr